This AP story reports on a new study presented at a cardiology meeting and published online via the New England Journal of Medicine. The research is particularly newsworthy because of the dramatic effects on both LDL (“bad”) and HDL (“good”) cholesterol. The story was better in a number of ways than the competing USA Today coverage of the same study. (Please note: we reviewed the first version of each story that we found – not any subsequent versions the news orgs may have published.) Important caveats were conveyed up front and potential conflicts were described more completely. In addition, this story presented the data on patients’ cholesterol levels before and after treatment, and compared them with what is considered healthy; USA Today only provided the percentage change in cholesterol. Both stories contained quotes that were overly optimistic, but this story avoided the worst excesses that the USA Today piece succumbed to. This story could have been improved with the inclusion of at least some information about the likely costs of the drug, if approved.
Cardiovascular disease remains number one cause of death in the US and other developed countries. And many people still suffer heart attacks despite being treated with high doses of statin drugs, which lower bad cholesterol. So researchers are looking for new ways to lower bad cholesterol further or increase good cholesterol, which might also help reduce risk. But it’s not enough to show that a drug has beneficial effects on these measures, which are only markers for heart disease risk. We also need data showing that the drug actually prevents heart attacks and deaths.
As with the competing USA Today coverage, this story didn’t mention costs. We feel that some discussion of this issue was warranted.
The story did a better job than the competing USA Today coverage of focusing on what was actually shown in the study. Importantly, it told us the average good and bad cholesterol levels for drug and placebo-treated patients before and after treatment. It also told us how these levels compare with those that are considered healthy. By contrast, the USA Today story only provided the percentage increase and decrease, and didn’t tell us whether the patients achieved targets associated with reduced disease risk.
We learn that the new drug doesn’t raise blood pressure the same way its predecessor, torcetrapib, did, but we don’t learn that the new drug lowered LDL cholesterol to levels that might not be safe in 17.6% of patients, who had to stop taking the medicine.
This story was better than the competing USA Today piece on several fronts. Most notably, it cautioned within the first three paragraphs that we don’t know whether the cholesterol benefits seen in this study will translate into reduced risk of heart attacks and deaths. We have to wade to the bottom of the USA Today piece before any similar reservations are expressed. Similarly, while the story contains some syrupy quotes, it avoids the worst excesses that we saw in the USA Today coverage.
With that being said, we think the story could have done a better job of tempering the enthusiasm of some these sources.
For example, an NPR online story concluded:
“Still there were four deaths from cardiovascular causes among the 800 patients taking Merck’s drug compared with just one among the same number in the the just-released trial results. So don’t count Merck’s drug approved just yet.”
Several sources not affiliated with the study are quoted. And, unlike the competing coverage, the story points out that the story was funded by Merck and that several investigators on the study consulted for Merck and other drug makers. Still, could they find no one who was skeptical of the practical value of such a drug?
The story mentions that niacin can also be effective for individuals with low HDL cholesterol. The story might have also pointed out that statins are effective for the majority of people who have high LDL cholesterol.
The story notes that this drug won’t be on the market anytime soon.
The story tells us that the new drug would be “the first of its kind,” but we also learn about the problems seen with a competing drug that worked through similar mechanisms.
The story does not appear to be based on a news release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like